ClearPoint Neuro said that Ernesto Salegio, PhD, will be joining its biologics and drug delivery team as vice president and segment leader for translational and preclinical research.
Salegio comes to ClearPoint Neuro with over 19 years of experience in translational neuroscience, including over 16 years of gene therapy experience working with adeno-associated viral vectors. The appointment is effective March 1.
ClearPoint Neuro launched its biologics and drug delivery team in 2020 to provide a range of services for pharmaceutical and academic partners working on gene and stem cell therapies for the brain, according to the firm.